All treatments
Treatment
200 mg concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)
This study is looking into new combinations of medicines for people with a type of liver cancer that can be removed with surgery. It aims to see how well these new treatments work before surgery and if they are safe.
For: Hepatocellular Carcinoma (Morpheus-Neo HCC)Austria · Spain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
This study is testing a new drug, Ezurpimtrostat, alongside standard treatments (Atezolizumab and Bevacizumab) for advanced liver cancer that can't be removed by surgery. It aims to see how well this new combination stops the cancer from growing.
For: unresectable hepatocellular carcinomaFrance